Table 2 Intervention, respiratory support, parameters, and complications
Variable | HFNC success (n = 115) | HFNC failure (n = 133) | P value |
|---|---|---|---|
Treatment, number (%) | |||
 Systemic corticosteroids | 115 (100) | 133 (100) |  |
 Remdesivir | 76 (66.1) | 72 (54.1) | 0.06 |
 Tocilizumab | 101 (84.2) | 110 (77.2) | 0.26 |
Complication | |||
 Gastroenteric bleeding (%) | 1 (0.9) | 8 (6.0) | 0.02 |
 Hospital-acquired pneumonia (%) | 9 (7.8) | 42 (31.6) |  < 0.0001 |
 Bacteremia (%) | 3 (2.6) | 19 (14.3) | 0.0006 |
 Length of hospital stay, day [IQR] | 13 [11–19] | 25 [17.5–42.5] |  < 0.0001 |
 28-day mortality, number (%) |  | 16 (12.0) |  |
HFNC and respiratory support | |||
 HFNC flow, 40 L/min, number (%) | 115 (100) | 133 (100) |  |
 Admission to start HFNC use, days | 1 [0–2] | 0 [0–0] |  < 0.0001 |
 RR after starting HFNC, /min | 22 ± 6 | 25 ± 6 | 0.002 |
 S/F ratio after starting HFNC | 157.2 ± 32.6 | 137.6 ± 35.2 |  < 0.0001 |
 ROX index after starting HFNC | 7.68 ± 3.01 | 6.04 ± 2.49 |  < 0.0001 |
 ROX index < 4.88, number (%) | 18 (15.7) | 49 (36.8) | 0.0001 |
 ICU stay, number (%) | 75 (65.2) | 133 (100) |  |
 Awake prone position, number (%) | 23 (20.0) | 21 (15.8) | 0.38 |
 Intubation and MV, number (%) |  | 133 (100) |  |